Fidaxomicin

證據等級: L5

預測適應症: 9 個

Fidaxomicin: From Clostridioides difficile Infection to Staphylococcal Scalded Skin Syndrome

One-Sentence Summary

Fidaxomicin is a narrow-spectrum macrolide antibiotic whose established use is treating Clostridioides difficile infection (CDI), acting locally in the gut with minimal systemic absorption. The TxGNN model predicts it may be effective for Staphylococcal Scalded Skin Syndrome (SSSS), but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying rationale explicitly flags a mechanistic contradiction rather than support.

Quick Overview

Item	Content
Original Indication	Clostridioides difficile infection (CDI) — not present in local license records, but referenced consistently across the evidence pack’s mechanistic analysis
Predicted New Indication	Staphylococcal Scalded Skin Syndrome
TxGNN Prediction Score	99.71%
Evidence Level	L5 (model prediction only, no clinical trials or literature)
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed, structured mechanism-of-action data for fidaxomicin is currently a data gap. Based on information available elsewhere in the evidence pack, fidaxomicin is a narrow-spectrum macrolide that inhibits bacterial RNA polymerase and is used for CDI specifically because it acts locally within the gut lumen — it is almost not systemically absorbed after oral dosing.

SSSS, by contrast, is not primarily a bacterial-burden problem: it is caused by exfoliative toxins produced by Staphylococcus aureus and requires drug exposure at the skin/systemic level to have any therapeutic effect. Because fidaxomicin’s defining pharmacokinetic property is the absence of meaningful systemic or dermal concentration, the evidence pack’s own mechanistic rationale for this candidate concludes it is “only a TxGNN score association, without substantive mechanism or clinical support.”

In short, the antimicrobial spectrum may theoretically overlap with S. aureus, but the route/exposure requirements of SSSS are incompatible with how fidaxomicin actually behaves in the body. This is a case where the prediction score is high but the underlying pharmacology argues against, rather than for, repurposing.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Fidaxomicin currently holds no active license records in this dataset (0 NDAs; market status: Not Marketed). No authorization details are available to tabulate.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high, but there are zero clinical trials and zero publications supporting this specific indication (Evidence Level L5), and the evidence pack’s own mechanistic analysis argues that fidaxomicin’s negligible systemic absorption makes it pharmacologically unsuited to a toxin-mediated, exposure-dependent skin condition like SSSS. This is a low-confidence, model-only signal.

To proceed, the following is needed:

Verified mechanism-of-action and pharmacokinetic data (systemic/dermal exposure levels) from DrugBank or primary literature
TFDA/FDA labeling data (warnings, contraindications) — currently a blocking data gap
Any preclinical or in-vitro data specifically testing fidaxomicin activity in toxin-mediated staphylococcal skin disease, given the mechanistic contradiction identified above
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.